Why Niagen Bioscience, Inc.’s (NAGE) Stock Is Down 7.71%
As of Thursday, October 01, Niagen Bioscience, Inc.’s NAGE share price has dipped by 7.71%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Consumer Staples | Personal Care Products |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Cynthia McLaughlin
Cynthia McLaughlin
Michael Rose
Jenna Brashear
| Share Statistics | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $221.2 | $273.8 | 28% |
|
| Shares Out (Mil) | 82.5 | 33.5 | 58% |
|
| Institutional Ownership | 64.3% | 59.8% | 40% |
|
| Float (Mil) | 59.1 | 44.0 | 51% |
|
| Beta | 2.10 | 0.54 | 93% |
|
| Avg Daily Volume (000s) | 617 | 120 | 61% |
|
| Price Change (52-week) |
(64.6%) | 53.3% | 12% |
|
| Growth | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.9% | (0.1%) | 77% |
|
| Net Income (5yr) | 23.5% | (8.6%) | 78% |
|
| EPS (5yr) | 21.2% | (1.3%) | 70 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 59.5% | (15.9%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.010) | $0.090 | $0.100 | |
| Month Ago EPS | ($0.010) | $0.090 | $0.100 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $0.030 | $0.190 | $0.290 | |
| Year/Year Chg | (200.0%) | (55.0%) | 25.0% | |
| Financials | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $129 | $650 | 28% |
|
| Net Income (TTM) (Mil) | $16 | $-0 | 48% |
|
| EPS (TTM) | $0.201 | $0.000 | 46% |
|
| Operating Cash Flow (TTM) (Mil) | $6 | $27 | 36% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $1 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $39 | 18% |
|
| Enterprise Value (Q1) (Mil) | $172 | $379 | 25% |
|
| Valuation | NAGE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.68 | 1.69 | 63% |
|
| P/E | 14.7 | 14.9 | 38% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.7 | 0.6 | 35% |
|
| Ratios | NAGE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.2% | 61.0% | 76% |
|
| Net Margin | 12.4% | 1.7% | 68% |
|
| ROA | 16.1% | (0.3%) | 94% |
|
| ROE | 21.8% | 0.8% | 81% |
|
| Liabilities to Assets | 22.6% | 48.9% | 15% |
|
| F-Score | 5 | 4 | 50% |
|
Niagen Bioscience, Inc. did not pass any screens on 10/2/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors